- AU$117.08m
- AU$101.16m
- AU$6.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 16.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.78% | ||
| Return on Equity | n/a | ||
| Operating Margin | -494.15% | ||
Financial Summary
| Year End 30th Jun | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0 | 0.04 | 0.58 | 5.91 | 6.98 | 69 | n/a | 440.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Directors
- James Williams NEC (45)
- Nina Webster CEO
- Hamish George CFO
- Kathryn Harrison COO
- David Packham OTH
- Ash Soman EXB
- Hugh Alsop NED
- Sonia Poli NED (53)
- Last Annual
- June 30th, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- May 13th, 1975
- Public Since
- July 5th, 1989
- No. of Shareholders
- 7,029
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 600,396,776
- Address
- 425 Smith Street, Fitzroy, MELBOURNE, 3065
- Web
- https://dimerix.com/
- Phone
- +61 300813321
- Contact
- Nina Webster
- Auditors
- Stantons International
Latest News for DXB
Upcoming Events for DXB
Dimerix Ltd Annual Shareholders Meeting
Half Year 2027 Dimerix Ltd Earnings Release
Similar to DXB
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
As of Today at 20:17 UTC, shares in Dimerix are trading at AU$0.20. This share price information is delayed by 15 minutes.
Shares in Dimerix last closed at AU$0.20 and the price had moved by -62.86% over the past 365 days. In terms of relative price strength the Dimerix share price has underperformed the ASX All Ordinaries Index by -61.09% over the past year.
The overall consensus recommendation for Dimerix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreDimerix does not currently pay a dividend.
Dimerix does not currently pay a dividend.
Dimerix does not currently pay a dividend.
To buy shares in Dimerix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.20, shares in Dimerix had a market capitalisation of AU$117.08m.
Here are the trading details for Dimerix:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: DXB
Based on an overall assessment of its quality, value and momentum Dimerix is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dimerix. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -48.19%.
As of the last closing price of AU$0.20, shares in Dimerix were trading -37.17% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Dimerix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Dimerix's management team is headed by:
- James Williams - NEC
- Nina Webster - CEO
- Hamish George - CFO
- Kathryn Harrison - COO
- David Packham - OTH
- Ash Soman - EXB
- Hugh Alsop - NED
- Sonia Poli - NED